Astria Therapeutics Analyst Ratings
Astria Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/12/2023 | 176.92% | HC Wainwright & Co. | $20 → $18 | Maintains | Buy |
| 08/08/2023 | 284.62% | Wedbush | $26 → $25 | Maintains | Outperform |
| 08/08/2023 | 207.69% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 06/08/2023 | 361.54% | Oppenheimer | → $30 | Reiterates | Outperform → Outperform |
| 05/12/2023 | 300% | Wedbush | → $26 | Reiterates | → Outperform |
| 05/12/2023 | 207.69% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 03/28/2023 | 176.92% | Evercore ISI Group | → $18 | Initiates Coverage On | → Outperform |
| 02/24/2023 | 207.69% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 12/19/2022 | 207.69% | HC Wainwright & Co. | $13 → $20 | Maintains | Buy |
| 09/29/2021 | 207.69% | Jefferies | → $20 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月12日 | 176.92% | HC Wainwright公司 | $20→$18 | 維護 | 買 |
| 2023/08/08 | 284.62% | 韋德布什 | $26→$25 | 維護 | 跑贏大盤 |
| 2023/08/08 | 207.69% | HC Wainwright公司 | →$20 | 重申 | 購買→購買 |
| 06/08/2023 | 361.54% | 奧本海默 | →$30 | 重申 | 跑贏→跑贏大盤 |
| 2023年05月12日 | 百分之三百 | 韋德布什 | →$26 | 重申 | →跑贏大盤 |
| 2023年05月12日 | 207.69% | HC Wainwright公司 | →$20 | 重申 | 購買→購買 |
| 03/28/2023 | 176.92% | Evercore ISI集團 | →$18 | 開始承保 | →跑贏大盤 |
| 02/24/2023 | 207.69% | HC Wainwright公司 | →$20 | 重申 | →購買 |
| 2022年12月19日 | 207.69% | HC Wainwright公司 | $13→$20 | 維護 | 買 |
| 09/29/2021 | 207.69% | 傑富瑞 | →$20 | 開始承保 | →購買 |
What is the target price for Astria Therapeutics (ATXS)?
Astria Treeutics(ATXS)的目標價格是多少？
The latest price target for Astria Therapeutics (NASDAQ: ATXS) was reported by HC Wainwright & Co. on October 12, 2023. The analyst firm set a price target for $18.00 expecting ATXS to rise to within 12 months (a possible 176.92% upside). 9 analyst firms have reported ratings in the last year.
阿斯特裡亞治療公司(納斯達克代碼：ATXS)的最新目標價是由HC Wainwright&Co.於2023年10月12日報道的。這家分析公司將目標價定為18美元，預計ATXS將在12個月內上漲至(可能上漲176.92%)。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Astria Therapeutics (ATXS)?
Astria Treateutics(ATXS)的最新分析師評級是什麼？
The latest analyst rating for Astria Therapeutics (NASDAQ: ATXS) was provided by HC Wainwright & Co., and Astria Therapeutics maintained their buy rating.
阿斯特裡亞治療公司(納斯達克代碼：ATXS)的最新分析師評級由HC Wainwright&Co.提供，阿斯特裡亞治療公司維持買入評級。
When is the next analyst rating going to be posted or updated for Astria Therapeutics (ATXS)?
Astria Treeutics(ATXS)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Astria Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Astria Therapeutics was filed on October 12, 2023 so you should expect the next rating to be made available sometime around October 12, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查看公共財務報表，與Astria Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Astria治療公司的上一次評級是在2023年10月12日提交的，所以你應該預計下一次評級將在2024年10月12日左右的某個時候提供。
Is the Analyst Rating Astria Therapeutics (ATXS) correct?
分析師對Astria Treeutics(ATXS)的評級正確嗎？
While ratings are subjective and will change, the latest Astria Therapeutics (ATXS) rating was a maintained with a price target of $20.00 to $18.00. The current price Astria Therapeutics (ATXS) is trading at is $6.50, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Astria Treateutics(ATXS)評級保持不變，目標價在20.00美元至18.00美元之間。Astria Treateutics(ATXS)目前的交易價格為6.50美元，超出了分析師的預測區間。